ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. More Details
No risks detected for ICLR from our risk checks.
Flawless balance sheet and slightly overvalued.
Share Price & News
How has ICON's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ICLR is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: ICLR's weekly volatility (4%) has been stable over the past year.
7 Day Return
US Life Sciences
1 Year Return
US Life Sciences
Return vs Industry: ICLR underperformed the US Life Sciences industry which returned 37% over the past year.
Return vs Market: ICLR underperformed the US Market which returned 20.7% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is ICON's share price compared to the market and industry in the last 5 years?
Simply Wall St News
4 days ago | Simply Wall StWill Weakness in ICON Public Limited Company's (NASDAQ:ICLR) Stock Prove Temporary Given Strong Fundamentals?
2 weeks ago | Simply Wall StICON (NASDAQ:ICLR) Has A Rock Solid Balance Sheet
Is ICON undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: ICLR ($191.14) is trading above our estimate of fair value ($140.81)
Significantly Below Fair Value: ICLR is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: ICLR is good value based on its PE Ratio (31.5x) compared to the US Life Sciences industry average (41.8x).
PE vs Market: ICLR is poor value based on its PE Ratio (31.5x) compared to the US market (19.7x).
Price to Earnings Growth Ratio
PEG Ratio: ICLR is poor value based on its PEG Ratio (1.9x)
Price to Book Ratio
PB vs Industry: ICLR is good value based on its PB Ratio (5.9x) compared to the US Life Sciences industry average (6.6x).
How is ICON forecast to perform in the next 1 to 3 years based on estimates from 16 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ICLR's forecast earnings growth (16.6% per year) is above the savings rate (2.2%).
Earnings vs Market: ICLR's earnings (16.6% per year) are forecast to grow slower than the US market (22% per year).
High Growth Earnings: ICLR's earnings are forecast to grow, but not significantly.
Revenue vs Market: ICLR's revenue (9% per year) is forecast to grow slower than the US market (10.2% per year).
High Growth Revenue: ICLR's revenue (9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ICLR's Return on Equity is forecast to be low in 3 years time (19.4%).
How has ICON performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ICLR has high quality earnings.
Growing Profit Margin: ICLR's current net profit margins (11.6%) are lower than last year (13.1%).
Past Earnings Growth Analysis
Earnings Trend: ICLR's earnings have grown by 9% per year over the past 5 years.
Accelerating Growth: ICLR's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: ICLR had negative earnings growth (-11.1%) over the past year, making it difficult to compare to the Life Sciences industry average (30.4%).
Return on Equity
High ROE: ICLR's Return on Equity (19.4%) is considered low.
How is ICON's financial position?
Financial Position Analysis
Short Term Liabilities: ICLR's short term assets ($1.8B) exceed its short term liabilities ($1.2B).
Long Term Liabilities: ICLR's short term assets ($1.8B) exceed its long term liabilities ($111.1M).
Debt to Equity History and Analysis
Debt Level: ICLR's debt to equity ratio (20.4%) is considered satisfactory.
Reducing Debt: ICLR's debt to equity ratio has reduced from 40.6% to 20.4% over the past 5 years.
Debt Coverage: ICLR's debt is well covered by operating cash flow (144.9%).
Interest Coverage: ICLR's interest payments on its debt are well covered by EBIT (45.2x coverage).
What is ICON current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ICLR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ICLR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ICLR's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ICLR's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ICLR's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Steve Cutler (60 yo)
Dr. Steven A. Cutler, also known as Steve, Ph.D., MBA, has been the Chief Executive Officer of ICON Public Limited Company since March 01, 2017, Dr. Cutler is the Chief Operating Officer of ICON at ICON C...
CEO Compensation Analysis
Compensation vs Market: Steve's total compensation ($USD7.69M) is about average for companies of similar size in the US market ($USD10.83M).
Compensation vs Earnings: Steve's compensation has been consistent with company performance over the past year.
|CEO & Director||3.67yrs||US$7.69m||0.058% |
|Chief Financial Officer||8.75yrs||US$2.24m||0.028% |
|Chief Administrative Officer||4.33yrs||no data||no data|
|Vice President of Corporate Finance & Investor Relations||no data||no data||no data|
|Chief Information Officer||no data||no data||no data|
|Executive Vice President of Investor Relations & Corporate Development||8.08yrs||no data||no data|
|Director of Corporate Communications||no data||no data||no data|
|Chief Human Resources Officer||4.33yrs||no data||no data|
|Executive Vice President of Program Management||1.83yrs||no data||no data|
|Senior Vice President of Global Clinical Pharmacology||11.58yrs||no data||no data|
|Managing Director of US Operations - ICON Central Laboratories||no data||no data||no data|
|Senior Vice President of Drug Development Services - CNS||13.83yrs||no data||no data|
Experienced Management: ICLR's management team is seasoned and experienced (6.2 years average tenure).
|CEO & Director||3.67yrs||US$7.69m||0.058% |
|Independent Non-Executive Director||6.75yrs||US$320.00k||no data|
|Founder & Independent Non-Executive Director||10.83yrs||US$308.00k||1.16% |
|Independent Non-Executive Director||3.08yrs||US$260.00k||no data|
|Non-Executive Chairman of the Board||3.67yrs||US$516.00k||no data|
|Independent Non-Executive Director||7.75yrs||US$337.00k||no data|
|Lead Independent Director||1.83yrs||US$330.00k||no data|
|Independent Non-Executive Director||3yrs||US$269.00k||no data|
|Independent Non-Executive Director||6.58yrs||US$320.00k||no data|
|Independent Non-Executive Director||1.33yrs||US$113.00k||no data|
Experienced Board: ICLR's board of directors are considered experienced (4.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
ICON Public Limited Company's company bio, employee growth, exchange listings and data sources
- Name: ICON Public Limited Company
- Ticker: ICLR
- Exchange: NasdaqGS
- Founded: 1990
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$9.935b
- Shares outstanding: 52.78m
- Website: https://www.iconplc.com
Number of Employees
- ICON Public Limited Company
- South County Business Park
- Co. Dublin
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|IJF||DB (Deutsche Boerse AG)||Yes||Ordinary Shares||DE||EUR||May 1998|
|ICLR||NasdaqGS (Nasdaq Global Select)||Yes||Ordinary Shares||US||USD||May 1998|
ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the U...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/11/27 23:49|
|End of Day Share Price||2020/11/27 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.